Y-mAbs to be acquired by SERB for $412M ($8.60/share, 105% premium); Q2 rev $19.5M

Y-mAbs Therapeutics, Inc.

SERB Pharmaceuticals to acquire Y-mAbs for $412M ($8.60/share cash), 105% premium to Aug 4 close; close expected Q4 2025.
Q2 total revenue $19.5M, above guidance of $17-19M; DANYELZA net product revenue $19.0M (-17% YoY).
Net loss narrowed to $3.2M ($0.07/shr) from $9.2M ($0.21/shr) in Q2 2024, helped by $2.0M FX gains and prior-year litigation settlements.
Cash and equivalents $62.3M as of June 30, 2025; no guidance or conference call due to pending transaction.

item 2.02item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.